Durvalumab

Description

This page contains brief details about the drug durvalumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Durvalumab is an anticancer drug that belongs to the category of medicines known as Anti-PD-1 monoclonal antibodies. It was approved by the FDA in May 2017 to treat certain types of cancer.

Mechanism of Action of Durvalumab

It works by blocking a protein called programmed death-ligand 1 (PD-L1), which is found on the surface of certain cancer cells. When PD-L1 binds to its receptor on T cells, it can inhibit the immune system’s ability to recognize and attack cancer cells.  By blocking the interaction between PD-L1 and its receptor, durvalumab allows T cells to recognize and attack cancer cells more effectively. Durvalumab helps the immune system to fight the cancer and potentially slow or stop its growth.

Uses of Durvalumab

Durvalumab is used to treat non-small cell lung cancer(has not spread outside your chest ), small cell lung cancer(has spread within your lungs), and biliary tract cancers(cancer of the bile ducts).

Durvalumab Dosage available

Durvalumab is a prescription drug available in injection form. This injection will be given intravenously into a vein in your arm or hand by a healthcare professional in a hospital setting. Do not self-administer this medicine. The dose of the injection will be decided by your doctor based on your disease condition and other factors. During the infusion, you will be monitored for any side effects or reactions to the medication. The infusion usually takes a few hours to complete, and you may need to receive multiple infusions over the course of several weeks.